Orphan Autoimmune Disorders to 2017 - Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market - GBI Research Reports

Orphan Autoimmune Disorders to 2017 - Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market

Orphan Autoimmune Disorders to 2017 - Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market - GBI Research Reports
Orphan Autoimmune Disorders to 2017 - Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market
Published Nov 22, 2011
88 pages — Published Nov 22, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Researchs report, Orphan Autoimmune Disorders to 2017 - Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market provides in-depth analysis of the drivers and barriers that affect the global orphan autoimmune disorders. The report analyzes the markets for orphan autoimmune disorders therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2017 for the leading therapeutic segments. The report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

GBI Research finds that the orphan autoimmune disorders market will show steady growth during the period 2010-2017. This growth will primarily be driven by the growth of the Idiopathic Thrombocytopenic Purpura (ITP) market, which has shown tremendous growth in terms of revenue between 2008 and 2010. Moreover, other key markets, such as myasthenia gravis and amyotrophic lateral sclerosis (ALS), will continue to grow steadily in the presence of very few molecules in the late stage of the product pipeline. The global orphan autoimmune disorders market is a niche market characterized by stiff competition from generics and off-label drugs and very few licensing agreements, co-development and M&A deals.

Scope

- Annualized market data for the orphan autoimmune disorders therapeutics market from 2002 to 2010, and forecast to 2017.
- Analysis of the leading therapeutic segments. These include ITP, myasthenia gravis and ALS.
- Analysis of the orphan autoimmune disorders therapeutic markets in the leading geographies of the world, which include the US, top five countries of Europe and Japan.
- Market characterization of the orphan autoimmune disorders (ITP, myasthenia gravis and ALS) market including market size, revenue analysis by top seven geographies, generic share, annual cost of therapy, and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of the pipeline molecules in various phases of drug development.
- Competitive benchmarking of the leading companies. The key companies studied in this report are Amgen Inc., GlaxoSmithKline plc, CSL Behring LLC., Mitsubishi Tanabe Pharma Corporation and Biogen Idec.
- Key M&A activities and licensing agreements that have taken place between 2004 and 2011 in the global orphan autoimmune disorders therapeutics market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of the leading companies.

  
Source:
Document ID
GBIHC149MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents36
  List of Tables62
  List of Figures81
Orphan Autoimmune Disorders to 2017 - Introduction92
  Overview91
  GBI Research Report Guidance101
Orphan Autoimmune Disorders to 2017 - Market Characterization116
  Market Forecasts111
    Revenue112
    Market Share of Orphan Diseases131
    Generic/Off-Label Share141
  Drivers and Restraints for the Global Orphan Autoimmune Disorders Therapeutics Market151
    Market Drivers151
      Strong Performance by Existing Branded Drugs and Expected Launch of Promising Products151
      High Unmet Needs and Orphan Drug Status to New Molecules151
    Market Restraints151
      Low Prevalence of Orphan Autoimmune Disorders151
      Lack of Specific Diagnostic Tests151
      Intense Competition from Generics and Off-Label Drugs161
Orphan Autoimmune Disorders to 2017 - Geographical Landscape176
  Revenue Analysis by Geography172
  The US191
    Revenue191
  Top Five Countries of Europe201
    Revenue201
  Japan211
    Revenue212
Orphan Autoimmune Disorders to 2017 - Therapeutic Landscape2331
  Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Forecasts231
    Disease Overview232
    Revenue251
    Generic Share261
    Revenue Analysis by Country272
    Annual Cost of Treatment291
    Treatment Usage Patterns301
      Diseased Population311
      Treatment Seeking Population311
      Diagnosed Population311
      Treated Population311
    Major Marketed Products321
      Nplate (Romiplostim)321
      Promacta/Revolade (Eltrombopag)321
      Rhophylac (Rh0 (D) Immune Globulin (Human))321
  Drivers and Restraints of the ITP Therapeutics Market331
    Market Drivers331
      Strong Performance by Existing Therapies for Chronic ITP to Drive the Market331
      High Unmet Needs and Orphan Drug Status to New Molecules Meant to Treat ITP331
      High Treatment seeking Population331
    Market Restraints331
      Lack of Specific Diagnostic Tests331
      Absence of Novel Specific Therapies in the R&D Pipeline331
  Global Myasthenia Gravis Therapeutics Market Forecasts341
    Disease Overview341
    Revenue351
    Generic Share361
    Revenue Analysis by Country372
    Annual Cost of Treatment391
    Treatment Usage Patterns401
      Diseased Population411
      Treatment Seeking Population411
      Diagnosed Population411
      Treated Population421
    Major Marketed Products421
      Mestinon (Pyridostigmine Bromide)421
  Drivers and Restraints of the Myasthenia Gravis Therapeutics Market421
    Market Drivers421
      Expected Launch of Promising Immunoglobulin Therapy to Drive the Market421
      Growth in the Treated Population421
    Market Restraints421
      Low Treatment Seeking Rate421
      Generic Dominance and Absence of Branded Drugs421
  Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Forecasts431
    Disease Overview431
    Revenue442
    Revenue Analysis by Country462
      Generic Share481
    Annual Cost of Treatment491
    Treatment Usage Patterns501
      Disease Population511
      Treatment Seeking Population511
      Diagnosis Population511
      Treated Population511
    Major Marketed Products521
      Rilutek (Riluzole)521
  Drivers and Restraints of the ALS Therapeutics Market521
    Market Drivers521
      Expected Launch of Promising Pipeline Molecules Will Drive the Growth of ALS Market In Future521
      The Rise in Awareness Among ALS Patients May Drive the ALS Market521
      High Unmet Needs and Orphan Drug Status for New Molecules Targeting ALS521
    Market Restraints521
      Low Diagnosis Rate521
      Patent Expiry of Rilutek531
Orphan Autoimmune Disorders to 2017 - Pipeline Analysis5413
  Research and Development Pipeline by Phase541
  Research and Development Pipeline by Indication551
  Idiopathic Thrombocytopenic Purpura (ITP): Research and Development Pipeline561
    Overview561
    Pipeline by Clinical Phases of Development571
      Preclinical571
      Phase I571
      Phase II571
      Phase III571
  Myasthenia Gravis: Research and Development Pipeline581
    Overview581
    Pipeline by Clinical Phases of Development591
      IND Filled591
      Phase II591
      Phase III/NDA Filed591
  Amyotrophic Lateral Sclerosis (ALS): Research and Development Pipeline601
    Overview601
    Pipeline by Clinical Phases of Development611
      Discovery611
      Preclinical/IND Filed621
      Phase I631
      Phase II631
      Phase III641
  Promising Drugs under Clinical Development for Orphan Autoimmune Disorders641
    Venoglobulin-IH641
      Overview641
      Mechanism of Action641
      Clinical Trial Management641
    Gammaplex651
      Overview651
      Mechanism of Action651
      Clinical Trial Management651
    IGIV3I Grifols651
      Overview651
      Mechanism of Action651
      Clinical Trial Management661
    Olesoxime (TRO19622)661
      Overview661
      Mechanism of Action661
      Clinical Trial Management661
Orphan Autoimmune Disorders to 2017 - Competitive Profiling676
  Amgen Inc.671
    Company Overview671
    Marketed Products for Orphan Autoimmune Disorders671
    SWOT Analysis671
  GlaxoSmithKline681
    Company Overview681
    Marketed Products for Orphan Autoimmune Disorders681
    SWOT Analysis681
  CSL Behring LLC691
    Company Overview691
    Marketed Products for Orphan Autoimmune Disorders691
    SWOT Analysis691
  Mitsubishi Tanabe Pharma Corporation701
    Company Overview701
    Orphan Autoimmune Disorders- R&D Pipeline701
    SWOT Analysis701
  Biogen Idec.711
    Company Overview711
    Orphan Autoimmune Disorders- R&D Pipeline711
    SWOT Analysis721
Orphan Autoimmune Disorders to 2017 - Strategic Consolidations738
  Overview731
  Segmentation by Year741
  Segmentation by Indication751
  Segmentation by Geography761
  Segmentation by Deal Value771
  Major Mergers and Acquisitions (M&A)781
  Major Licensing Agreements791
  Major Co-Development Deals801
Orphan Autoimmune Disorders to 2017 - Appendix818
  Market Definitions811
  Abbreviations811
  Research Methodology826
    Coverage821
    Secondary Research831
    Primary Research831
    Therapeutic Landscape841
    Epidemiology-based Forecasting842
    Market Size by Geography861
    Geographical Landscape871
    Pipeline Analysis871
    Competitive Landscape871
    Expert Panel Validation871
  Contact Us871
  Disclaimer871
  Sources881

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Orphan Autoimmune Disorders to 2017 - Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market" Nov 22, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Orphan-Autoimmune-Disorders-to-2017-Strong-Performance-by-Nplate-and-Promacta-and-Future-Launches-of-Immunoglobulin-Therapies-will-Drive-the-ITP-Market-2115-304>
  
APA:
GBI Research Reports. (2011). Orphan Autoimmune Disorders to 2017 - Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market Nov 22, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Orphan-Autoimmune-Disorders-to-2017-Strong-Performance-by-Nplate-and-Promacta-and-Future-Launches-of-Immunoglobulin-Therapies-will-Drive-the-ITP-Market-2115-304>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.